Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)  >>  Phase N/A
Welcome,         Profile    Billing    Logout  

3 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
NCT02012309: Mechanisms of Impaired HIV-associated B Cell and Pneumococcal Vaccine Responses

Active, not recruiting
N/A
60
US
PCV-13, Prevnar, PPSV-23, Pneumovax
University of Colorado, Denver, National Institute of Allergy and Infectious Diseases (NIAID)
HIV, Pneumococcal Infections, Pneumococcal Vaccines
06/21
06/21
Pneumo-CLL, NCT05145101: Pneumococcal Vaccination in Patients With Chronic Lymphocytic Leukaemia

Recruiting
N/A
150
Europe
Prevnar13, Pneumovax23
Hannah Garcia Garrido
Pneumococcal Infections, Chronic Lymphocytic Leukemia, Vaccine-Preventable Diseases, Invasive Pneumococcal Disease, Recurrent Isolated
03/22
03/22
NCT04845945: MISP 60528 Pneumococcal Vaccination

Recruiting
N/A
45
US
PCV15, PPS23, PCV15 and PPS23
Montefiore Medical Center, Merck Sharp & Dohme LLC
Heart Transplant Infection Prevention
07/25
07/25

Download Options